Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 3/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27706022 | 1.00 | ALOX5 (0.34) | ALOX5HTR2AHTR2CNLRP3IDH2 | |
| SCHEMBL4253756 | 0.89 | CES2 (0.43) | ALOX5NLRP3GUSBKMT2AMEN1 | |
| SCHEMBL4256668 | 0.85 | ALOX5 (0.36) | ALOX5HTR2AHTR2CNLRP3GUSB | |
| SCHEMBL27706116 | 0.85 | ALOX5 (0.36) | ALOX5HTR2AHTR2CNLRP3GUSB | |
| SCHEMBL5536783 | 0.84 | ALOX5 (0.36) | ALOX5HTR2AHTR2CNLRP3GUSB | |
| SCHEMBL4261561 | 0.84 | ALOX5 (0.36) | ALOX5HTR2AHTR2CNLRP3GUSB | |
| SCHEMBL4620011 | 0.84 | HTR2A (0.41) | HTR2AHTR2CKCNH2KMT2AMEN1 | |
| SCHEMBL27717789 | 0.84 | HTR2A (0.41) | HTR2AHTR2CKCNH2KMT2AMEN1 | |
| SCHEMBL5418921 | 0.83 | PTGES2 (0.47) | HTR2AHTR2CKCNH2PTGES2 | |
| SCHEMBL27717780 | 0.83 | PTGES2 (0.47) | HTR2AHTR2CKCNH2PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904471-B1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | claimed |
| CN-101208325-A | Heteroarylvinyl derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | claimed |
| US-7208506-B2 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | claimed |
| EP-1904471-B1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | disclosed |
| CN-101208325-A | Heteroarylvinyl derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
| US-7208506-B2 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | CYP3A43, CYP1A1, CYP3A5 | ALOX5 641/4885HTR2A 871/4885HTR2C 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.